Entity

Time filter

Source Type


Khodakaram-Tafti A.,Shiraz University | Shirian S.,Shiraz University | Shekarforoush S.S.,Shiraz University | Fariman H.,The Iranian Veterinary Organization | Daneshbod Y.,Daneshbod Pathology Laboratory
Comparative Clinical Pathology | Year: 2011

A 3-year-old Holstein cow with a history of severe weakness, dyspnea, pale mucous membranes, increased respiratory rate associated with marked abdominal respiration, severe arrhythmia, and tachycardia was referred to a slaughterhouse by the referring veterinarian due to poor prognosis. After slaughter, a large, firm, white, multilobulated mass about 5 cm in diameter was located at the base of the heart that extended to the right atrium and obliterated partially the right atrial lumen. Microscopically, tumor cells were aligned along and around the capillaries and were discrete, cuboidal to polyhedral cells with little cytoplasm arranged in distinct packets surrounded by thin fibrous septa. The nuclei were round to oval and were placed centrally in the cells. Immunoreactivity for S100 protein was positive multifocally, mostly in the peripherally located sustentacular cells, but NSE and CrA were negative. On the basis of the clinicopathological and immunohistochemical findings, the tumor was diagnosed as aortic body chemodectoma. © 2011 Springer-Verlag London Limited. Source


Omidvari S.,Shiraz University of Medical Sciences | Hamedi S.H.,Shiraz University of Medical Sciences | Moaddab-Shoar L.,Shiraz University of Medical Sciences | Nasrollahi H.,Shiraz University of Medical Sciences | And 6 more authors.
Iranian Journal of Cancer Prevention | Year: 2014

Paratesticular sarcomas have happened rarely. Due to the infrequency of this malignant disease and its diverse histopathologic subtypes, no standard treatment would be available. Multiple treatments have reported in literature with different results. We have reported a 55 years old man with a 30 years history of paratesticular mass. After multiple operations, radical orchiectomy has revealed liposarcoma. The patient has been receiving 50 Gy radiation to the scrotum and inguinal area. After 18 months follow up, the patient was well and disease free. He has shown good response to surgery and radiotherapy, so we have reported the disease and its clinical course. © 2014, Cancer Research Center. All rights reserved. Source


Shahbazi M.,Pasteur Institute of Iran | Shahbazi M.,Isfahan University of Medical Sciences | Zahedifard F.,Pasteur Institute of Iran | Taheri T.,Pasteur Institute of Iran | And 9 more authors.
PLoS ONE | Year: 2015

Canine Visceral Leishmaniasis (CVL) is a major veterinary and public health problem caused by Leishmania infantum (L. infantum) in many endemic countries. It is a severe chronic disease with generalized parasite spread to the reticuloendothelial system, such as spleen, liver and bone marrow and is often fatal when left untreated. Control of VL in dogs would dramatically decrease infection pressure of L. infantum for humans, since dogs are the main domestic reservoir. In the past decade, various subunits and DNA antigens have been identified as potential vaccine candidates in experimental animal models, but none has been approved for human use so far. In this study, we vaccinated outbreed dogs with a prime-boost regimen based on recombinant L. tarentolae expressing the L. donovani A2 antigen along with cysteine proteinase genes (CPA and CPB without its unusual C-terminal extension (CPB-CTE) and evaluated its immunogenicity and protective immunity against L. infantum infectious challenge. We showed that vaccinated animals produced significantly higher levels of IgG2, but not IgG1, and also IFN-γ and TNF-α, but low IL-10 levels, before and after challenge as compared to control animals. Protection in dogs was also correlated with a strong DTH response and low parasite burden in the vaccinated group. Altogether, immunization with recombinant L. tarentolae A2-CPA-CPB-CTE was proven to be immunogenic and induced partial protection in dogs, hence representing a promising live vaccine candidate against CVL. © 2015 Shahbazi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Source

Discover hidden collaborations